Alex Denner has taken a seat with the board of directors at Ariad--a position he demanded back in October when the company's only approved drug, Iclusig, ran into major safety concerns.
Ariad Pharmaceuticals just relaunched its leukemia drug Iclusig last week, but already buyout rumors are buzzing. The U.S.-based biotech saw its shares jump this morning on reports that Eli Lilly is leading a field of several potential buyers.
Ariad Pharmaceuticals is back in the market with Iclusig. The FDA is allowing the Cambridge, MA-based company to again sell the leukemia drug, but with tighter restrictions to face. Ariad has a lot of ground to regain to return to its former glory.
The European Medicines Agency has decided to look again at the clotting risks of Ariad Pharmaceuticals' troubled cancer drug Iclusig.
Drugmaker Ariad left its European operations untouched last month when it took an ax to its workforce after the FDA requested it pull its leukemia drug Iclusig off the market in the U.S. Regulators in the EU did not make the same request, but they also did not ignore the clotting risks that raised a red flag at the FDA.
Ariad Pharmaceuticals is letting go of nearly half its U.S. staff just a week after pulling its leukemia drug Iclusig from the market at the FDA's request.
After investigators tracked a rising rate of blood clots among leukemia patients in ongoing clinical studies, the biotech slammed the brakes on new trial enrollment and rolled out a lower dosing schedule for current participants.
After fast-tracking it, the FDA approved Ariad Pharmaceuticals' closely watched leukemia drug ponatinib today, a product that analysts say could generate blockbuster sales.
Good news came for GlaxoSmithKline ($GSK) Tuesday after the FDA's Oncologic Drugs Advisory Committee voted 11 to 2 in favor of approving Votrient to treat patients with advanced soft tissue sarcoma who have received prior chemotherapy. The FDA approved Votrient in 2009 to treat advanced renal cell carcinoma.